 |
 Video: What is a Stock Split?
|
|
|
| Ikena Oncology is a targeted oncology company developing medicines tailored to biomarker-defined patient groups. Co.'s programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment, with approaches to targeting both cancer driving targets and mechanisms of resistance to targeted therapies. Co.'s primary targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain transcription factor in the Hippo signaling pathway. Co.'s clinical-stage programs also include product candidates in development to target immune signaling in the tumor microenvironment. According to our Ikena Oncology stock split history records, Ikena Oncology has had 0 splits. | |
|
Ikena Oncology (IKNA) has 0 splits in our Ikena Oncology stock split history database.
Looking at the Ikena Oncology stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ikena Oncology shares, starting with a $10,000 purchase of IKNA, presented on a split-history-adjusted basis factoring in the complete Ikena Oncology stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/29/2021 |
|
| End date: |
04/17/2024 |
|
| Start price/share: |
$28.30 |
|
| End price/share: |
$1.24 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-95.62% |
|
| Average Annual Total Return: |
-64.08% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$438.17 |
|
| Years: |
3.05 |
|
|
|
|
|
